Anika Therapeutics (ANIK) Restructuring Costs (2013)
Anika Therapeutics' (ANIK) quarterly Restructuring Costs came in at $111178.0 in Q2 2013, down 18.01% on a QoQ basis from $135607.0 in Q1 2013.
Anika Therapeutics (ANIK) Restructuring Costs (2013) Analysis & Trends
Anika Therapeutics (ANIK) has 1 years of Restructuring Costs data on file, last reported at $111178.0 in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Anika Therapeutics | 198.50 Mn | 131.71 Mn | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 111,178.00 |
| Mar 31, 2013 | 135,607.00 |